Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Lower CTC count IDs indolent MBC disease subset
- Author:
- Sharon Worcester
A CTC count less than 5 per 7.5 mL of blood in MBC patients indicates an indolent disease subset, pooled data from two large cohorts show.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/July-2018/133889_Clegg_Lindsay_MD_web.jpg)
Trial data suggest beneficial class effects of SGLT2 inhibitors, including dapagliflozin
- Author:
- Sharon Worcester
ORLANDO – Data from EXSCEL placebo group subjects show beneficial class effects of SGLT2 inhibitors, including dapagliflozin, on MACE, ACM, and...
News
CVD-REAL 2: Lower mortality, CV risks with SGLT-2i vs. DPP-4i treatment in T2DM
- Author:
- Sharon Worcester
ORLANDO – SGLT2 inhibitor treatment, compared with DPP-4 inhibitors, is associated with lower death, CV event, and stroke rates in patients with...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/July-2018/Buse_John_Chapel Hill_web.jpg)
RISE: Insulin glargine, metformin offer no beta cell function benefit in youth
- Author:
- Sharon Worcester
ORLANDO – Findings from pediatric portions of RISE, a T2DM medication study, are disappointing but lay strong foundation for future studies in...
News
CANVAS data: Canagliflozin generally well tolerated up to 6.5 years
- Author:
- Sharon Worcester
The longest-term safety data to date show that canagliflozin is generally well tolerated for up to 6.5 years in patients with T2DM and high CV...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/July-2018/Khatri_Pooja_OHIO_web.jpg)
Alteplase, aspirin provide similar functional outcomes after nondisabling stroke
- Author:
- Sharon Worcester
PRISMS trial results suggest that alteplase offers no benefit over aspirin for functional outcomes after...
News
CANVAS program analysis: Canagliflozin benefits patients with T2DM and poor kidney function
- Author:
- Sharon Worcester
The cardioprotective benefits of canagliflozin in type 2 diabetes mellitus were similar across varying levels of kidney function in an analysis of...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/joaciam.jpg)
Intensive treatment for T2D pays off in the long run
- Author:
- Sharon Worcester
ORLANDO – Long-term follow-up of the Steno-2 study confirms that intensive therapy for type 2 diabetes saves money because of reduced...
News
KEYNOTE-427: Pembrolizumab monotherapy shows promise in accRCC
- Author:
- Sharon Worcester
CHICAGO – Pembrolizumab monotherapy shows promising efficacy and tolerability in treatment-naive patients with accRCC in the phase 2 KEYNOTE-427...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/screenshot_157.jpg)
Eversense CGM shown safe, accurate for 180 days in adolescents
- Author:
- Sharon Worcester
ORLANDO – The Eversense fully implantable CGM device, recently approved for adults in the U.S., is also safe and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/diabetes_blood_sugar_meter_web.jpg)
Average glucose, A1c discordance is common, highlights ADAG equation concerns
- Author:
- Sharon Worcester
ORLANDO - Significant discordance exists between average glucose (AG) and HbA1c measures in patients on insulin, according to findings...
Article
CAR T-cell approvals: multiple myeloma likely next up
- Author:
- Sharon Worcester
News
Blood and tissue TMB help predict checkpoint inhibition response in NSCLC
- Author:
- Sharon Worcester
High bTMB and tTMB appear to have value as biomarkers for checkpoint inhibition response in patients with NSCLC, according to data presented at...
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/screenshot_154.jpg)
PREOPANC-1: Early findings suggest benefit with preop chemo in pancreatic cancer
- Author:
- Sharon Worcester
Preliminary findings from the PREOPANC-1 trial suggest preoperative chemotherapy improves outcomes in pancreatic cancer patients.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/June-2018/capture_5.jpg)
Four phase 3 studies highlighted at ASCO mark progress in GI cancers
- Author:
- Sharon Worcester
Prodige 7 addressed a long-unanswered question about the value of HIPEC and demonstrated that less is more when it comes to the treatment of...